MedPath

A Clinical Study Of Effect of Virechana Karma in Manyastambha With Special Reference To Cervical Spondylosis.

Phase 2/3
Recruiting
Conditions
Other spondylosis. Ayurveda Condition: MANYASTAMBAH,
Registration Number
CTRI/2023/05/053121
Lead Sponsor
Sneha Shantaram Chanekar
Brief Summary

This study is randamized , controlled , clinical trial of add on effect of Virechana Karma with Eranadpaya 150ml in Manyastambha with special reference to cervical spindyliosis with oral administration of Erandmul Ghanavati 500mg BD And Anutail Nasya 8°-8° BD for 14 days. This  study is conducted as PG  Course at single centre.The Primary outcome  is to evaluate the effect of  Virechana Karma  in Manyastambha and Manyashoola with special reference to cervical spindyliosis.

Detailed Description

Not available

Recruitment & Eligibility

Status
Open to Recruitment
Sex
All
Target Recruitment
30
Inclusion Criteria

1.Patients fit for nasya and virechana karma.

Exclusion Criteria
  • Patients with Bahudoshavastha 38 2.
  • Patients with traumatic history of injury to spine.
  • Patients with long term infectious condition.
  • Patients with multiple drug therapy/steroids.
  • Pregnant or lactating women.
  • Critically ill patients.

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
To study the add on effect of Snehapurvak Virechana Karma along with oral administration of Erandmul Ghanvati and Anutail Nasya on Manyastambha and Manyashoola with special reference to cervical spondylosis.14 Days
Secondary Outcome Measures
NameTimeMethod
1.To compare the efficacy of trial regime with comntrol group in the management of Manyastambha.2.To evaluate the effect of Virechana on Range Of Motion of neck.

Trial Locations

Locations (1)

Government Ayurvedic College

🇮🇳

Nanded, MAHARASHTRA, India

Government Ayurvedic College
🇮🇳Nanded, MAHARASHTRA, India
Sneha Shantaram Chanekar
Principal investigator
8888348220
Chanekarsneha04@gmail.com

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.